Welcome to the Future of Cell & Gene Therapy

The 3rd In Vivo Cell Engineering & Gene Editing Summit is an annual event uniting C-level in vivo experts to facilitate safe and targeted in vivo delivery of payloads while providing clarity in regulations and appropriate models to advance the next frontier of in vivo editing from research to clinic.

Explore the full agenda – https://ter.li/snxcxi

As promising pre-clinical and proof of concept results continue to emerge, the ‘dream’ of in vivo cell engineering and gene editing is rapidly becoming a reality as numerous companies push towards the clinic.

Join us this July to network with and gain invaluable knowledge from our world-class speaker faculty from Capstan Therapeutics, Editas Medicine, NanoCell Therapeutics, Carisma Therapeutics, Sanofi, and more, offering exclusive insights into their strategies for staying ahead of the curve and shaping the future of cell and gene therapy in the years ahead.

Key Highlights:

• Exploring data-driven case studies to outline decision making when selecting viral versus non-viral vectors
• Clarifying regulatory expectations for this novel therapeutic approach to map out the future of your pipeline
• Benchmarking appropriate preclinical models to support translation to gain valuable data needed by regulatory bodies
• Outlining the considerations when scaling up towards the clinic to equip you with the tools to tackle bottlenecks
• Emphasizing target specificity and the mitigation off-site toxicities to ensure safety is front of mind in development

Register now for the best savings – https://ter.li/ssnrpz

#InVivoCellEngineeringandGeneEditingSummit